Biogen Inc. (BIIB)
NASDAQ: BIIB · Real-Time Price · USD
218.50
-3.00 (-1.35%)
At close: Aug 28, 2026, 4:00 PM EDT
218.19
-0.31 (-0.14%)
After-hours: Aug 28, 2026, 7:30 PM EDT
Biogen Financials Overview
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Revenue Revenue Growth | 10,028 | 9,891 | 9,676 | 9,836 | 10,173 | 10,982 |
Revenue Growth | 0.31% | 2.22% | -1.62% | -3.32% | -7.36% | -18.32% |
Gross Profit Gross Profit Growth | 7,854 | 7,808 | 7,547 | 7,302 | 7,895 | 8,872 |
Operating Income Operating Income Growth | 2,516 | 2,848 | 2,614 | 1,899 | 3,019 | 3,436 |
Net Income Net Income Growth | 834.6 | 1,293 | 1,632 | 1,161 | 3,047 | 1,556 |
Earnings Per Share EPS Growth | 5.64 | 8.79 | 11.18 | 7.97 | 20.87 | 10.40 |
EPS Growth | -46.06% | -21.38% | 40.28% | -61.81% | 100.67% | -58.06% |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Multiple Sclerosis Product Multiple Sclerosis Product Growth | 3,900 | 4,039 | 4,350 | 4,662 | 5,430 | 6,097 |
Rare Disease Product Rare Disease Product Growth | 2,207 | 2,154 | 1,988 | 1,803 | 1,794 | 1,905 |
Biosimilars Product Biosimilars Product Growth | 701.6 | 729.1 | 793.1 | 770 | 751.1 | 831.1 |
Other Product Other Product Growth | 247.2 | 197.2 | 82.5 | 11.8 | 13 | 14 |
Revenue (Total) Revenue (Total) Growth | 10,028 | 9,891 | 9,676 | 9,836 | 10,173 | 10,982 |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Investments Cash & Investments Growth | 1,285 | 4,248 | 2,375 | 1,050 | 5,599 | 4,695 |
Total Debt Total Debt Growth | 8,355 | 6,658 | 6,717 | 7,429 | 6,711 | 7,693 |
Net Cash (Debt) Net Cash Growth | -7,070 | -2,410 | -4,342 | -6,379 | -1,113 | -2,998 |
Net Cash Growth | - | - | - | - | - | - |
Net Cash Per Share Net Cash Per Share Growth | -47.75 | -16.38 | -29.76 | -43.81 | -7.62 | -20.04 |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Cash Flow Operating Cash Flow Growth | 2,879 | 2,205 | 2,876 | 1,547 | 1,384 | 3,640 |
Capital Expenditures CapEx Growth | -182.2 | -153.8 | -153.7 | -277 | -240.3 | -258.1 |
Free Cash Flow Free Cash Flow Growth | 2,697 | 2,051 | 2,722 | 1,270 | 1,144 | 3,382 |
Free Cash Flow Growth | 36.28% | -24.65% | 114.28% | 11.03% | -66.17% | -11.12% |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Gross Margin | 78.32% | 78.95% | 78.00% | 74.24% | 77.61% | 80.79% |
Operating Margin | 25.09% | 28.79% | 27.02% | 19.30% | 29.67% | 31.29% |
Pretax Margin | 10.09% | 15.74% | 19.70% | 13.18% | 35.33% | 16.21% |
Profit Margin | 8.32% | 13.07% | 16.87% | 11.80% | 29.95% | 14.17% |
FCF Margin | 26.89% | 20.73% | 28.13% | 12.91% | 11.24% | 30.80% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Aug '26 Aug 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 38.75 | 19.97 | 13.65 | 32.29 | 13.09 | 22.65 |
Forward PE | 16.54 | 13.66 | 9.71 | 17.54 | 17.70 | 13.94 |
P/FCF Ratio | 11.97 | 12.59 | 8.19 | 29.52 | 34.86 | 10.42 |
PS Ratio | 3.22 | 2.61 | 2.30 | 3.81 | 3.92 | 3.21 |